Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(19)30684-9

License

CC-BY

Other Formats

PDF